VCAM-1

There are 117 papers on VCAM-1 in aging research: 23 trials and 40 observational studies in people, 30 in animals, 9 in cells, 15 reviews. The newest story, Oct 28, 2026: “Soybean carbohydrate improved blood vessel function in aged mice”.

Biomarker

117 papers study it39 more mention it31 findings

8 new papers in 30 daysSee all 156 papers on VCAM-1

“there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM (r2 = 0.24; P = 0.01)”
Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shockCritical care (London, England)2011doi:10.1186/cc10343
  • Human trial23
  • Humans40
  • Animals30
  • Cells9

Interventions

10

Aerobic exercise

downin humans2

2 studies
  1. Aerobic exercise decreases VCAM-1 in humans (isolated systolic hypertension).

    Human trialisolated systolic hypertension16 weeksfemales

  2. Aerobic exercise decreases VCAM-1 in humans.

    Human trial16 weeksfemalesn = 40

More on Aerobic exercise

Coenzyme Q10

no changein humans1downin humans1

2 studies
  1. Coenzyme Q10 decreases VCAM-1 in humans (overweight and obese women with polycystic ovary syndrome).

    Human trialoverweight and obese women with polycystic ovary syndromecapsulesserum200 mg/day8 weeksfemalesn = 43

  2. Coenzyme Q10 showed no clear effect on VCAM-1 in humans (SMD: -0.34, 95% CI: -0.74 to -0.06, p < 0.10).

    Review

More on Coenzyme Q10

Quercetin

no changein humans2

2 studies
  1. Quercetin showed no clear effect on VCAM-1 in humans (post-myocardial infarction) (P = 0.80).

    Human trialpost-myocardial infarction500 mg/day8 weeksn = 88

  2. Quercetin showed no clear effect on VCAM-1 in patients with metabolic syndrome and related disorders (WMD -24.49, 95% CI -53.74 to 4.77).

    Reviewin patients with metabolic syndrome and related disorders

More on Quercetin

Synbiotics

downin humans1

1 study
  1. Synbiotics decrease VCAM-1 in humans.

    Human trial4 monthsn = 96

  2. Synbiotics decrease VCAM-1 in humans (type 2 diabetes and high cardiovascular risk) (-85.70 ng/L (-150.14 to -21.26)).

    Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85

More on Synbiotics

Semaglutide

upin humans1

1 study
  1. Semaglutide increases VCAM-1 in humans (compared with placebo; also seen in the semaglutide plus empagliflozin combination group) (12.3 (95% CI 2.8 to 20.8) vs placebo).

    Human trialcompared with placebo; also seen in the semaglutide plus empagliflozin combination group32 weeks

More on Semaglutide

Carica papaya

downin humans1

1 study
  1. Carica papaya decreases VCAM-1 in humans following a Mediterranean diet.

    Human trialfollowing a Mediterranean diet3 months

More on Carica papaya

Mesenchymal stem cells

downin mice1

1 study
  1. Mesenchymal stem cells decrease VCAM-1 in mice treated with SKL-MSCs.

    Animalsin mice treated with SKL-MSCsengineered with secreted Klotho (SKL-MSCs)brainfemales

More on Mesenchymal stem cells

Curcumin

downin humans1

1 study
  1. Curcumin decreases VCAM-1 in humans (WMD: -39.19 ng/mL; 95 % CI: -66.15, -12.23).

    Review

More on Curcumin

Resveratrol

no changein humans1

1 study
  1. Resveratrol showed no clear effect on VCAM-1 in humans.

    Review

More on Resveratrol

Resistance training

upin mice1

1 study
  1. Resistance training increases VCAM-1 in Snell dwarf mice.

    Animalsin Snell dwarf miceskeletal muscle

More on Resistance training

Effects

2

Cognitive function

no changein humans1

1 study
  1. VCAM-1 was not clearly linked with cognitive function in humans (cognitively unimpaired).

    Humanscognitively unimpairedn = 313

Delirium

no changein humans1

1 study
  1. VCAM-1 was not clearly linked with delirium in humans (elective surgery).

    Humanselective surgeryblood7th postoperative dayn = 788

More on Delirium

Associations

14

Coenzyme Q10

downin humans1

1 study
  1. Coenzyme Q10 is associated with VCAM-1 in patients with septic shock after adjusting for LDL levels (r2 = 0.24, P = 0.01).

    Human trialin patients with septic shock after adjusting for LDL levelsn = 14

  2. Coenzyme Q10 is associated with VCAM-1 in humans.

    Humansmaximum of seven days or until hospital dischargen = 14

More on Coenzyme Q10

Handgrip strength

downin humans1

1 study
  1. VCAM-1 is associated with handgrip strength in humans.

    Humansn = 427

Sarcopenia

upin humans1OR 3.573

1 study
  1. VCAM-1 is associated with sarcopenia in humans (VCAM-1 ≥796.59 pg/mL; multivariate-adjusted association) (Adjusted OR 3.573, 95% CI 1.839–6.834).

    HumansVCAM-1 ≥796.59 pg/mL; multivariate-adjusted associationserumn = 427

More on Sarcopenia

Subclinical atherosclerotic plaque

upin humans1

1 study
  1. VCAM-1 predicts subclinical atherosclerotic plaque in humans (at baseline).

    Humansat baseline

More on Subclinical atherosclerotic plaque

Older donor age

upin human cells1

1 study
  1. Older donor age is associated with VCAM-1 in human cells (Older-adult-derived versus middle-aged-derived cells).

    CellsOlder-adult-derived versus middle-aged-derived cellsCD146+ bone marrow stromal cell-conditioned media

Psychological stress

upin humans1

1 study
  1. Psychological stress is associated with VCAM-1 in humans (cognitively normal middle-aged adults with parental history of AD) (r=.352, p = .033).

    Humanscognitively normal middle-aged adults with parental history of ADcsfmostly female (66%)sn = 50

More on Psychological stress

Cognitive resilience

downin humans1

1 study
  1. Cognitive resilience is associated with VCAM-1 in humans (resilient APOE ε4 carriers) (p < 0.01).

    Humansresilient APOE ε4 carriersplasma3+ yearsn = 300

Cognition-impaired cerebral small vessel disease

upin humans1OR 1.15

1 study
  1. VCAM-1 is associated with cognition-impaired cerebral small vessel disease in humans (Rothwell's CSVD burden score; cognitive impairment defined as MoCA scores < 26) (OR 1.15, 95% CI 1.05–1.25).

    HumansRothwell's CSVD burden score; cognitive impairment defined as MoCA scores < 2650.9% of malessn = 2,596

More on Cognition-impaired cerebral small vessel disease

Cerebral small vessel disease burden

upin humans1

1 study
  1. VCAM-1 is associated with cerebral small vessel disease burden in humans (Wardlaw's and Rothwell's CSVD burden scores) (Wardlaw: cOR 1.11, 95% CI 1.02–1.21; Rothwell: cOR 1.16, 95% CI 1.07–1.25).

    HumansWardlaw's and Rothwell's CSVD burden scores50.9% of malessn = 2,596

Cerebral small vessel disease

upin humans1OR 1.16

1 study
  1. VCAM-1 is associated with cerebral small vessel disease in humans (Presence defined using Rothwell's CSVD burden score) (OR 1.16, 95% CI 1.06–1.26).

    HumansPresence defined using Rothwell's CSVD burden score50.9% of malessn = 2,596

More on Cerebral small vessel disease

All 14

Latest

Dec 2025: 6Jan 2026: 8Feb 2026: 4Mar 2026: 4Apr 2026: 1May 2026: 2Jun 2026: 1Jul 2026: 4Aug 2026: 11Sep 2026: 2Oct 2026: 7Nov 2026: 353 papers in 12 months
Journal of Agricultural and Food Chemistry

Soybean carbohydrate improved blood vessel function in aged mice

In 20-month-old mice, 12 weeks of supplementation restored blood vessel relaxation controlled by the vessel lining and reduced signs of inflammation.In 20-month-old mice, 12 weeks of supplementation restored blood vessel relaxation controlled by the vessel lining and reduced signs of inflammation.

Mouse studyInterventions
Frontiers in Aging Neuroscience

Spinal fluid protein linked to Alzheimer’s dementia risk

An observational study of 444 people without dementia linked a blood vessel-related protein to poorer thinking, brain shrinkage and later Alzheimer’s dementia.An observational study of 444 people without dementia linked a blood vessel-related protein to poorer thinking, brain shrinkage and later Alzheimer’s dementia.

Cohort study of 444 peopleAlzheimer's disease

See all 156 papers on VCAM-1